News Image

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American Academy of Pain Medicine (AAPM) 2025 Annual Meeting

Provided By GlobeNewswire

Last update: Apr 7, 2025

TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable activity in treating fibromyalgia

TNX-102 SL demonstrated statistically significant improvement in the primary endpoint of reduction in fibromyalgia pain in two pivotal double-blind randomized Phase 3 studies

Read more at globenewswire.com

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (7/23/2025, 8:00:00 PM)

After market: 45.72 +0.2 (+0.44%)

45.52

+0.77 (+1.72%)



Find more stocks in the Stock Screener

Follow ChartMill for more